CONTACT
+91 80 2808 2808
info@biocon.com
Biocon  /  Businesses  /  Generics  /  Access

GENERIC FORMULATIONS

Strategy: Access

Affordability

Affordability creates accessibility and we aim to achieve this through efficiency, scale, vertical integration and global development programs.

Presence

Our commercial strategy is a mix of our direct presence in select markets and a B2B partnering model for geographies that require a strong local presence to create the reach. We are adopting a phased approach and have addressed the following markets in Phase 1.

USA: We have a direct presence to commercialise our generic formulations portfolio. We are commercial with three products which have a mid to high teen market share for our drug products and more will be added through new product approvals and filings.

China: We have licensed out three products to China Medical System (CMS) for commercialisation. Biocon will be responsible for the development, registration and manufacturing of the formulations. Similar collaborative models will expand our presence in this market.

Europe: We have a two-prong approach to address the region’s diverse distribution channels. UK, Germany and the Nordic region will see a direct presence under the Biocon label. For other geographies, we are pursuing a B2B commercialisation strategy

Brazil: We plan to pursue a collaborative B2B business model for commercialisation, which will leverage our development and manufacturing strengths in complex generics and our partner’s strong local presence.

Siddharth Mittal
KEY MANAGEMENT TEAM
PRODUCTS
PRESS RELEASES
CORPORATE GOVERNANCE
R&D
WORKING WITH US
Share
Previous Next
Close
Test Caption
Test Description goes like this